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Osteoarthritis is a common complex disease with huge public health burden. Here we 
perform a genome-wide association study for osteoarthritis using data across 16.5 
million variants from the UK Biobank resource. Following replication and meta-
analysis in up to 30,727 cases and 297,191 controls, we report 9 new osteoarthritis 
loci, in all of which the most likely causal variant is non-coding. For three loci, we 
detect association with biologically-relevant radiographic endophenotypes, and in 
five signals we identify genes that are differentially expressed in degraded compared 
to intact articular cartilage from osteoarthritis patients. We establish causal effects for 
higher body mass index, but not for triglyceride levels or genetic predisposition to 
type 2 diabetes, on osteoarthritis.  
 
INTRODUCTION 
Osteoarthritis is the most prevalent musculoskeletal disease and the most common form of 
arthritis1. The hallmarks of osteoarthritis are degeneration of articular cartilage, remodelling 
  
of the underlying bone and synovitis2. A leading cause of disability worldwide, it affects 40% 
of individuals over the age of 70 and is associated with an increased risk of comorbidity and 
death3. The health economic burden of osteoarthritis is rising, commensurate with longevity 
and obesity rates, and there is currently no curative therapy. The heritability of osteoarthritis 
is ~50%, and previous genetic studies have identified 21 loci in total, traversing hip, knee 
and hand osteoarthritis with limited overlap3. Here we conduct the largest osteoarthritis 
genome wide association study (GWAS) to date, using genotype data across 16.5 million 
variants from UK Biobank. We define osteoarthritis based on both self-reported status and 
through linkage to Hospital Episode Statistics data, and on joint-specificity of disease (knee 
and/or hip) (Supplementary Fig. 1). 
 
RESULTS 
Disease definition and power to detect genetic associations 
We compare and contrast the hospital diagnosed (n=10,083 cases) to self-reported 
(n=12,658 cases) osteoarthritis GWAS drawn from the same UK Biobank dataset (with non-
osteoarthritis controls selected to be ~4x the number of cases to preserve power for 
common alleles while avoiding case:control imbalance causing association tests to 
misbehave for low frequency variants4) (Supplementary Tables 1-3, Supplementary Figs. 2-
4; Methods). We find power advantages with the self-reported dataset, indicating that the 
increase in sample size overcomes the limitations associated with phenotype uncertainty. 
When evaluating the accuracy of disease definition, we find that self-reported osteoarthritis 
has modest positive predictive value (PPV=30%) and sensitivity (37%), but a high negative 
predictive value of 95% and high specificity, correctly identifying 93% of individuals who do 
not have osteoarthritis (Supplementary Table 4). In terms of power to detect genetic 
associations, the self-reported osteoarthritis dataset has clear advantages commensurate 
with its larger samples size (Figure 1). For example, for a representative complex disease-
associated variant with minor allele frequency (MAF) 30% and allelic odds ratio 1.10, the 
self-reported and hospital diagnosed osteoarthritis analyses have 80% and 56% power to 
detect an effect at genome-wide significance (i.e., P<5.0x10-8), respectively (Supplementary 
Table 5).  
 
We find nominally significant evidence for concordance between the direction of effect at 
previously reported osteoarthritis loci and the discovery analyses for hospital diagnosed 
osteoarthritis definitions (Supplementary Table 6, Supplementary Table 7, Supplementary 
note), indicating that a narrower definition of disease may provide better effect size 
estimates albeit limited by power to identify robust statistical evidence for association. 
 
Heritability estimates across osteoarthritis definitions 
We find that common-frequency variants explain 12% of osteoarthritis heritability when using 
self-reported status, and 16% when using hospital records (19% of hip osteoarthritis and 
15% of knee osteoarthritis heritability) (Supplementary Table 8). Heritability estimates from 
self-reported and hospital records were not significantly different from each other 
(Supplementary Table 9). The concordance between self-reported and hospital diagnosed 
osteoarthritis was further substantiated by the high genetic correlation estimate of the two 
disease definitions (87%, P=3.14x10-53) (Supplementary Table 10). We find strong genome-
wide correlation between hip osteoarthritis and knee osteoarthritis (88%, P=1.96x10-6), even 
though previously reported osteoarthritis loci are predominantly not shared between the two 
osteoarthritis joint sites. Based on this new observation of a substantial shared genetic 
aetiology, we sought replication of association signals across joint sites. 
 
Identification of novel osteoarthritis loci 
We took 173 variants with P<1.0x10-5 and MAF>0.01 forward to replication in an Icelandic 
cohort of up to 18,069 cases and 246,293 controls (Supplementary Fig. 1, Supplementary 
Tables 11-15; Methods). Given the number of variants, the replication significance threshold 
was P<2.9x10-4. Following meta-analysis in up to 30,727 cases and 297,191 controls, we 
  
report six genome-wide significant associations at novel loci, and three further replicating 
signals just below the corrected genome-wide significance threshold (Table 1, Figure 2). 
 
We identify association between rs2521349 and hip osteoarthritis (OR 1.13 (95% CI 1.09-
1.17), P= 9.95x10-10, effect allele frequency [EAF] 0.37). rs2521349 resides in an intron of 
MAP2K6 on chromosome 17. MAP2K6 is an essential component of the p38 MAP kinase 
mediated signal transduction pathway, involved in various cellular processes in bone, 
muscle, fat tissue homeostasis and differentiation5. The MAPK signalling pathway has been 
closely associated with osteoblast differentiation6, chondrocyte apoptosis and necrosis7, and 
reported to be differentially expressed in osteoarthritis synovial tissue samples6-12. In animal 
model studies, its activity has been found to be important in maintaining cartilage health and 
it has been proposed as a potential osteoarthritis diagnosis and treatment target10,13,14.  
 
rs11780978 on chromosome 8 is also associated with hip osteoarthritis with a similar effect 
size (OR 1.13 (95% CI 1.08-1.17), p=1.98x10-9, EAF 0.39). This variant is located in the 
intronic region of the plectin gene, PLEC. We find rs11780978 to be nominally associated 
with the radiographically derived endophenotype of minimal joint space width (beta -0.0291, 
SE 0.0129, P=0.024) (Table 2; Methods). The direction of effect is consistent with the 
established clinical association between joint space narrowing and osteoarthritis. PLEC 
encodes plectin, a structural protein which interlinks components of the cytoskeleton. 
Functional studies in mice have shown an effect on skeletal muscle tissue and correlation 
with decreased body weight, size and postnatal growth15.  
 
rs2820436 is an intergenic variant located 24kb upstream of long non-coding RNA RP11-
392O17.1 and 142kb downstream of zinc finger CCCH-type containing 11B pseudogene 
ZC3H11B, and is associated with osteoarthritis across any joint site (OR 0.93 (95% CI 0.91-
0.95), P=2.01x10-9, EAF 0.65). It also resides within a region with multiple metabolic and 
anthropometric trait-associated variants, with which it is correlated (r2 0.18-0.88).  
 
rs375575359 resides in an intron of the zinc finger protein 345 gene, ZNF345, on 
chromosome 19. It was prioritised based on osteoarthritis at any joint site and is more 
strongly associated with knee osteoarthritis in the replication dataset (OR 1.21 (95% CI 1.14-
1.30), P=7.54x10-9, EAF 0.04). Similarly, rs11335718 on chromosome 4 was associated with 
osteoarthritis in the discovery and knee osteoarthritis in the replication stage (OR 1.11 (95% 
CI 1.07-1.16), P= 4.26x10-8, EAF 0.10). We note that Bonferroni correction for the effective 
number of traits tested would mean that rs11335718 no longer reaches genome-wide 
significance with a meta-analysis P=4.26x10-8. rs11335718 is an intronic variant in the 
annexin A3 gene, ANXA3. By meta-analysing the any site osteoarthritis phenotype across 
the discovery and replication datasets, we report P=2.6x10-5 and P=1.32x10-7 for 
rs375575359 and rs11335718, respectively (Supplementary Table 11). A recent mouse 
model study supports the involvement of a similar motif zinc finger protein expression 
(ZFP36L1) with osteoblastic differentiation16. 
 
rs3771501 (OR 0.94 (95% CI 0.92-0.96), P=1.66x10-8, EAF 0.53) is associated with 
osteoarthritis at any site and resides in an intron of the transforming growth factor alpha 
gene, TGFA. TGFA encodes an epidermal growth factor receptor ligand and is an important 
integrator of cellular signalling and function. We detect association of rs3771501 with 
minimal joint space width (beta -0.0699, SE 0.0127, P=3.45x10-8) (Table 2; Methods), i.e. 
the osteoarthritis risk increasing allele is also associated with decreased joint cartilage 
thickness in humans. A perfectly correlated variant in this gene has previously been 
associated with cartilage thickness, suggestively associated with hip osteoarthritis, and 
found to be differentially expressed in osteoarthritis cartilage lesions compared to non-
lesioned cartilage17. Functional studies have revealed that TGFA regulates the conversion of 
cartilage to bone during the process of endochondral bone growth, that it is a dysregulated 
cytokine present in degrading cartilage in osteoarthritis and a strong stimulator of cartilage 
  
degradation upregulated by articular chondrocytes in experimentally induced and human 
osteoarthritis18-21. The function of TGFA has also been associated with craniofacial 
development, palate closure and decreased body size22. 
 
rs864839 resides in the intronic region of the junctophilin 3 gene, JPH3, on chromosome 16, 
and was discovered based on the any joint site osteoarthritis analysis. It is more strongly 
associated with hip osteoarthritis in the replication dataset (OR 1.08 (95% CI 1.05-1.11), 
P=2.1x10-8, EAF 0.71). By meta-analysing the any site osteoarthritis phenotype across the 
discovery and replication datasets, we report P=7.02x10-6 (Supplementary Table 11). JPH3 
is involved in the formation of junctional membrane structure, regulates neuronal calcium flux 
and is reported to be expressed in pancreatic beta cells and in the regulation of insulin 
secretion.  
 
rs116882138 is most strongly associated with hip and/or knee osteoarthritis in the discovery 
and with knee osteoarthritis in the replication dataset (OR 1.34 (95% CI 1.21-1.49), 
P=5.09x10-8, EAF 0.02). It is an intergenic variant located 11kb downstream of the kinase 
activator 3B gene, MOB3B, and 16kb upstream of the equatorin, sperm acrosome 
associated gene, EQTN, on chromosome 9. We find rs116882138 to be nominally 
associated with acetabular dysplasia as measured with Center Edge-angle (beta -1.1388, 
SE 0.5276, P=0.031) (Table 2; Methods). 
 
Finally, rs6516886 was prioritised based on the hip and/or knee osteoarthritis discovery 
analysis and is more strongly associated in the hip osteoarthritis replication dataset (OR 1.10 
(95% CI 1.06-1.14), p=5.84x10-8, EAF 0.75). rs6516886 is situated 1kb upstream of the 
RWD domain containing 2B gene, RWDD2B, on chromosome 21. LTN1 (listerin E3 ubiquitin 
protein ligase 1), which resides at a distance of 28kb from the variant, has been reported to 
affect musculoskeletal development in a mouse model23. 
 
Functional analysis 
We tested whether coding genes within 1Mb surrounding the novel osteoarthritis-associated 
variants were differentially expressed at 1% false discovery rate (FDR)  in chondrocytes 
extracted from intact compared to degraded cartilage from osteoarthritis patients undergoing 
total joint replacement surgery using molecular phenotyping through quantitative proteomics 
and RNA sequencing (Table 3; Methods).  
 
PCYOX1, located 209kb downstream of rs3771501, showed significant evidence of 
differential expression (1.21-fold higher post-normalisation in degraded cartilage at the RNA 
level, q-value=0.0047; and 1.17-fold lower abundance at the protein level, q=0.0042). This 
discrepancy could signal potential clinical relevance, as the gene product constitutes a 
candidate biomarker for osteoarthritis progression. Prenylcysteine oxidase 1, the protein 
product of this gene, catalyses the degradation of prenylated proteins24, is a secreted 
protein, and has been identified in urinary exosomes25. Further investigation into the 
chondrocyte and peripheral secretome is warranted to assess the potential of this molecule 
as a biomarker for osteoarthritis progression. PCYOX1 has been reported to be 
overexpressed in human dental pulp derived osteoblasts compared to osteosarcoma cells26. 
FAM136A, located 188kb upstream of the same variant (rs3771501), showed 1.13-fold lower 
transcriptional levels in chondrocytes from degraded articular cartilage (q=0.0066).  
 
BACH1 and MAP3K7CL, located in the vicinity of rs6516886, showed evidence of differential 
transcription (1.26-fold, q=0.0019, and 1.37-fold, q=0.0021, higher transcription in degraded 
tissue, respectively). BACH1 is a transcriptional repressor of Heme oxygenase-1 (HO-1). 
Studies in Bach1 deficient mice have independently suggested inactivation of Bach1 as a 
novel target for the prevention and treatment of meniscal degeneration27 and of 
osteoarthritis28.  
 
  
Finally, PLAA and ZNF382 located proximal to rs116882138 and rs375575359, respectively, 
showed higher transcription levels in degraded compared to intact cartilage (1.15-fold, 
q=0.0027, and 1.31-fold, q=0.0031, respectively). BOP1 located 451kb downstream of 
rs11780978 showed 1.17-fold lower levels of transcription in degraded tissue (q=0.003). 
 
We examined evidence for expression quantitative trait loci (eQTLs) in GTEx tissues and 
found that none of the eQTLs identified at 5%FDR overlapped with the genes identified as 
differentially expressed between osteoarthritis intact and degraded cartilage (Supplementary 
Note; Supplementary Table 16). 
 
Fine-mapping points to non-coding variants at all loci 
For five of the new loci, the sum of probabilities of causality of all variants in the fine-mapped 
region was ≥0.95 (>0.99 for two signals), and for two further loci it was >0.93 
(Supplementary Table 17; Methods). The majority of variants within each credible set have 
marginal posterior probabilities, while only a small number of variants have posterior 
probability of association (PPA) >0.1; these account for 25-92% of PPA across the different 
regions. The credible set of four signals can be narrowed down to 3 variants, one signal to 2 
variants, and one signal to 1 variant with a probability of causality >0.1. For all 9 regions the 
variant identified as the most likely to be causal is non-coding (Supplementary Table 18, 
Supplementary note, Supplementary Fig. 5).  
 
Gene-based analyses 
Gene set analysis identified UQCC1 and GDF5, located in close vicinity to each other on 
chromosome 20, as key genes with consistent evidence for significant association with 
osteoarthritis across phenotype definitions (Supplementary Table 19, Supplementary note). 
UQCC1 and GDF5 were significantly associated with four and three of the five osteoarthritis 
definitions, respectively. GDF5 codes for growth differentiation factor 5, a member of the 
TGFbeta superfamily, and there is accruing evidence that it play a central role in skeletal 
health and development29-32. Pathway analyses identified significant associations between 
self-reported osteoarthritis and anatomical structure morphogenesis (P=4.76x10-5), ion 
channel transport (P=8.98x10-5); hospital diagnosed hip osteoarthritis and activation of 
MAPK activity (P=1.61x10-5); hospital diagnosed knee osteoarthritis and histidine 
metabolism (P=1.02x10-5); and between hospital diagnosed hip and/or knee osteoarthritis 
and recruitment of mitotic centrosome proteins and complexes (P=8.88x10-5) 
(Supplementary Table 20, Supplementary Fig. 6).  
 
Genetic links between osteoarthritis and other traits 
Established clinical risk factors for osteoarthritis include increasing age, female sex, obesity, 
occupational exposure to high levels of joint loading activity, previous injury, smoking status 
and family history of osteoarthritis. We estimated the genome-wide genetic correlation 
between osteoarthritis and 219 other traits and diseases and identified 35 phenotypes with 
significant (5% FDR) genetic correlation with osteoarthritis across definitions, with large 
overlap between the identified phenotypes (Supplementary Fig. 7, Figure 3, Supplementary 
Table 21; Methods).  
 
The phenotypes with significant genetic correlations (rg) fall into the following broad 
categories: obesity, BMI and related anthropometric traits (rg>0); type 2 diabetes (rg>0); 
educational achievement (rg<0); neuroticism, depressive symptoms (rg>0), and sleep 
duration (rg<0); mother’s, father’s, or parents’ age at death (rg<0); reproductive phenotypes, 
including age at first birth (rg<0) and number of children ever born (rg>0); smoking, including 
age of smoking initiation (rg<0) and ever smoker (rg>0), and lung cancer (rg>0) (Figure 3, 
Supplementary Table 21). The four phenotypes with significant genetic correlation in all 
analyses were: years of schooling, waist circumference, hip circumference and BMI. 
 
  
We find a nominally significant positive genetic correlation with rheumatoid arthritis, which 
did not pass multiple-testing correction for self-reported and hospital diagnosed osteoarthritis 
(rg=0.14-0.19, FDR 10%-12%). Of musculoskeletal phenotypes, lumbar spine bone mineral 
density showed positive genetic correlation with hospital diagnosed hip and/or knee 
osteoarthritis (rg=0.2, FDR=3%) but did not reach significance in other analyses.  
 
Disentangling causality 
We undertook Mendelian randomisation (MR) analyses33 to strengthen causal inference 
regarding modifiable exposures that could influence osteoarthritis risk (Supplementary 
Tables 22-25; Methods). Each kg/m2 increment in body mass index was predicted to 
increase risk of self-reported osteoarthritis by 1.11 (95% CI: 1.07-1.15, P= 8.3x10-7). This 
result was consistent across MR methods (OR ranging from 1.52 to 1.66) and disease 
definition (OR ranging from 1.66 to 2.01). Consistent results were also observed for other 
obesity-related measures, such as waist (OR: 1.03 per cm increment; 95% CI: 1.02-1.05, 
P=5x10-4) and hip circumference (OR: 1.03 per cm increment; 95% CI: 1.01-1.06, P=0.021). 
OR for type 2 diabetes liability and triglycerides were consistently small in magnitude across 
estimators and osteoarthritis definitions; given that analyses involving those traits were well-
powered (Supplementary Table 26), these results are compatible with either a weak or no 
causal effect. Results for years of schooling were not consistent across estimators, and 
there was evidence of directional horizontal pleiotropy, thus hampering any causal 
interpretation (Figure 4). For lumbar spine bone mineral density, there was evidence of a 
causal effect with OR per standard deviation increment of 1.28 (95% CI: 1.11-1.47, P=0.002) 
for hip and/or knee osteoarthritis. This effect appeared to be site-specific, with OR of 1.29 
(95% CI: 1.06-1.57, P=0.014) for knee osteoarthritis, while OR for hip osteoarthritis ranged 
from 0.71 to 1.57. There was also some evidence for a site-specific causal effect of height 
on knee osteoarthritis (OR: 1.13 per standard deviation increment; 95% CI: 1.02-1.25, 
P=0.023), which was consistent across estimators. One-sample MR analyses corroborated 
these findings, with obesity-related phenotypes presenting strong statistical evidence after 
multiple testing correction (Supplementary Table 27). These analyses did not detect reliable 
effects of smoking or reproductive traits on osteoarthritis (Supplementary Tables 28 and 29). 
 
DISCUSSION 
In order to improve our understanding of the genetic aetiology of osteoarthritis, we have 
conducted a study combining genotype data in up to 327,918 individuals. We identify 6 
novel, robustly replicating loci associated with osteoarthritis, and three which fall just under 
the corrected genome-wide significance threshold; this constitutes a substantial increase in 
the number of known osteoarthritis loci. Taken together, all established osteoarthritis loci 
account for 26.3% of trait variance (Supplementary Fig. 8). The key attributes of this study 
are sample size and the homogeneity of the UK Biobank dataset, coupled with independent 
replication, independent association with clinically-relevant radiographic endophenotypes, 
and functional genomics follow up in primary osteoarthritis tissue. We have further 
capitalised on the wealth of available genome-wide summary statistics across complex traits 
to identify genetic correlations between osteoarthritis and multiple molecular, physiological 
and behavioural phenotypes, followed by formal Mendelian randomization analyses to 
assess causality and disentangle complex cross-trait epidemiological relationships.    
 
The vast majority of novel signals are at common frequency variants and confer small to 
modest effects, in line with a highly polygenic model underpinning osteoarthritis risk. We 
identify one low-frequency variant association with osteoarthritis (MAF 0.02) with a modest 
effect size (combined OR 1.34). Even though well-powered to detect them, we find no 
evidence for a role of low frequency variation of large effect in osteoarthritis susceptibility 
(Supplementary Table 5). The power of this study is very limited for low frequency variants 
with OR<1.50, and for rare variants. We estimate the requirement of up to 40,000 
osteoarthritis cases and 160,000 controls to recapitulate the effects identified in this study at 
  
genome-wide significance based on the sample size-weighted effect allele frequencies and 
replication cohort odds ratio estimates (Table 1, Supplementary Table 30).  
 
We integrated functional information with statistical evidence for association to fine-map the 
location of likely causal variants and genes. All predicted most likely causal variants reside in 
non-coding sequence: 6 are intronic and 3 are intergenic. We are able to refine the 
association signal to a single variant in one occasion, and to variants residing within a single 
gene in three instances, although the mechanism of action could be mediated through other 
genes in the vicinity. 
 
We empirically find self-reported osteoarthritis definition to be a powerful tool for genetic 
association studies, for example as evidenced by the fact that the established GDF5 
osteoarthritis locus reaches genome-wide significance in the self-reported disease status 
analyses only. Published epidemiological studies investigating osteoarthritis via self-
report34,35 and validation of self-reported status against primary care records has yielded 
similar conclusions34. We also find very high genetic correlation between self-reported and 
hospital diagnosed osteoarthritis, and similar variant-based heritability estimates, 
corroborating the validity of self-reported osteoarthritis status for genetic studies. However, 
we also note that the hospital diagnosed osteoarthritis analyses have higher heritability and 
yield stronger evidence for effect direction concordance at established loci, indicating that 
larger sample size would afford the power required to convincingly detect them. Hospital 
diagnosed data for osteoarthritis potentially capture a different patient demographic 
compared to self-reported data (Supplementary note). Based on the results of this study, we 
deduce that there is no gold standard for osteoarthritis definition in genetics studies, and 
identify advantages in employing both methods of defining disease to maximize discovery 
power across the board. 
 
We identify strong genome-wide correlation between hip and knee osteoarthritis, indicating a 
substantial shared genetic aetiology that has been hitherto missed. We therefore sought 
replication of signals across these highly correlated phenotypes and identify multiple 
instances of signals detected in the larger discovery analysis of osteoarthritis, and 
independently replicated in joint-specific definitions of disease. Indeed, when looking at the 
replication phenotypes, we find no instances of confirmed replication where the replication 
phenotype is not captured within the accompanying discovery phenotype definition. Further 
analysis in larger sample sets with precise phenotyping will help distinguish signal specificity. 
 
Two of the newly identified signals, indexed by rs11780978 and rs2820436, reside in regions 
with established metabolic and anthropometric trait associations. osteoarthritis is 
epidemiologically associated with increased BMI, and the association is stronger for knee 
osteoarthritis. In line with this, we find higher genetic correlation between BMI and knee 
osteoarthritis (rg=0.52, P=2.2x10-11), than with hip osteoarthritis (rg=0.28, P=4x10-4). BMI is 
also known to be genetically correlated with education phenotypes, depressive symptoms, 
reproductive and other phenotypes; hence, some of the genetic correlations for osteoarthritis 
observed here could be mediated through BMI. However, for the education and 
personality/psychiatric phenotypes, the strength of genetic correlations observed here for 
osteoarthritis is substantially higher than the genetic correlations observed for BMI (e.g. 
hospital diagnosed osteoarthritis and years of schooling rg=-0.45, P=5x10-27, while BMI and 
years of schooling have rg=-0.27, P=9x10-32; hospital diagnosed osteoarthritis and 
depressive symptoms rg=0.49, P=6x10-7, while BMI and depressive symptoms have 
rg=0.10, P=0.023). Epidemiologically, lower educational levels are known to be associated 
particularly with risk of knee osteoarthritis, even when adjusting for BMI36. 
 
Mendelian randomization provided further insight into the nature of the genetic correlations 
we observed. In the case of BMI and other obesity-related measures, there was evidence for 
a causal effect of those phenotypes on osteoarthritis. This result corroborates the findings 
  
from conventional observational studies37, which are prone to important limitations (such as 
reverse causation and residual confounding) regarding causal inference38. For all other 
exposure phenotypes, there was no convincing evidence for a causal effect on osteoarthritis 
risk, suggesting that the genetic correlations detected by LD score regression may be mostly 
due to horizontal pleiotropy, although for some phenotypes the MR analyses were 
underpowered (Supplementary Table 26). In the case of triglycerides and liability to type 2 
diabetes, the Mendelian randomization analyses had sufficient power to rule out non-small 
causal effects, suggesting that these phenotypes have at most weak effects on osteoarthritis 
risk.  
 
Crucially, structural changes in the joint usually precede the onset of symptoms for 
osteoarthritis. Articular cartilage is an avascular, aneural tissue. It provides tensile strength, 
compressive resilience and a low-friction articulating surface. Chondrocytes are the only cell 
type in cartilage. The mode of function of non-coding DNA is linked to context-dependent 
gene expression regulation, and identification of the causal variants and the genes they 
affect requires experimental analysis of genome regulation in the right cell type. Our 
functional analysis of genes in osteoarthritis-associated regions and pathways identified 
differentially expressed molecules in chondrocytes extracted from degraded compared to 
intact articular cartilage. Cartilage degeneration is a key hallmark of osteoarthritis 
pathogenesis and regulation of these genes could be implicated in disease development and 
progression.  
 
Osteoarthritis is a leading cause of disability worldwide and carries a substantial public 
health and health economics burden. Here, we have gleaned novel insights into the genetic 
aetiology of osteoarthritis, and have implicated genes with translational potential10,13,14,27,28. 
The cohorts contributing to this study were composed of European-descent populations. 
Going forward, large-scale whole genome sequencing studies of well-phenotyped individuals 
across diverse populations will capture the full allele frequency and variation type spectrum, 
and afford us further insights into the causes of this debilitating disease. 
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FIGURE LEGENDS 
Figure 1 
Power to detect association in the discovery stage. Odds ratios (ORs) and 95% 
confidence intervals as a function of minor allele frequencies (MAF). Newly reported variants 
are denoted in diamonds, while known variants are denoted in circles. The curves indicate 
80% power at the genome-wide significance threshold of P<5.0x10-8, for the number of 
cases and controls of each trait at the discovery stage. 
 
Figure 2 
Regional association plots for the nine novel osteoarthritis loci. The y axis represents 
the negative logarithm (base 10) of the variant P-value and the x axis represents the position 
on the chromosome, with the name and location of genes and nearest genes shown in the 
  
bottom panel. The variant with the lowest P-value in the region after combined discovery and 
replication is marked by a purple diamond. The same variant is marked by a purple dot 
showing the discovery P-value. The colours of the other variants indicate their r2 with the 
lead variant. 
 
Figure 3 
Heat map of genetic correlations between osteoarthritis phenotypes in UK Biobank 
and 35 traits grouped in 10 categories from GWAS consortia. Symbols and hues depict 
the FDR q-values and strength of the genetic correlation (darker shade denotes stronger 
correlation), respectively. Red and blue indicate positive and negative correlations, 
respectively. RP: reproductive; SL: sleep. 
 
Figure 4 
Two-sample Mendelian randomization estimates and 95% confidence intervals of the 
effect of obesity-related measures, triglyceride levels, years of schooling (in standard 
deviations units) and type 2 diabetes liability (in ln(odds ratio) units) on different 
definitions of osteoarthritis. 
HD: hospital diagnosed. IVW: inverse-variance weighting. MBE: mode-based estimate. MBE 
(1): tuning parameter 𝜑=1. MBE (0.5): tuning parameter 𝜑=0.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 1 
Association summary statistics for the nine signals. aImputation accuracy was assessed by IMPUTE-infoscore. bHeterogeneity P-values 
are derived from Cochran’s Q-test.  cThe number of cases required for 80% power is calculated on the basis of the replication study OR 
estimate, sample size-weighted effect allele frequency across the discovery and replication studies, and assuming 4 controls per case. dtwo 
sided P-value. EA, effect allele; EAF, effect allele frequency; OR, odds ratio; n, sample size. 
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Table 2  
Association of the 9 osteoarthritis loci with radiographically-derived osteoarthritis endophenotypes. aFor minimal joint space width, 
proxy variant rs2150403 (r2=0.99 with rs6516886) was used. bSample size=13,013. cSample size=6,880. dSample size cases=639. eSample 
size controls=4,339. ftwo sided p-value. EA: effect allele; EAF: effect allele frequency; SE: standard error; N/A: not available. 
 
 minimal joint space width
b  Center edge-anglec alpha angle (cam deformity)d,e 
rsID EA EAF Beta SE P-valuef EA EAF Beta SE P-valuef EA EAF Beta SE P-valuef 
rs2820436 A 0.317 -0.0146 0.0135 0.2817 A 0.317 -0.0104 0.1301 0.9363 A 0.318 0.0165 0.0675 0.8073 
rs3771501 A 0.484 -0.0699 0.0127 3.454E-08 A 0.474 0.1943 0.1199 0.1051 A 0.4779 -0.0144 0.0626 0.8176 
rs11335718 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
rs11780978 A 0.389 -0.0291 0.0129 0.02419 A 0.386 0.078 0.1239 0.5291 A 0.3866 0.0035 0.0644 0.9564 
rs2521349 A 0.398 0.0229 0.0128 0.07404 A 0.391 0.0998 0.1236 0.4192 A 0.3921 -0.0262 0.0644 0.6835 
rs864839 N/A N/A N/A N/A N/A T 0.702 -0.0206 0.1325 0.8766 T 0.7026 -0.0081 0.0691 0.907 
rs375575359 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
rs116882138 N/A N/A N/A N/A N/A A 0.0137 -1.1388 0.5276 0.0309 A 0.0135 0.1814 0.2607 0.4865 
rs6516886ᵃ T 0.272 -0.0222 0.0143 0.1206 A 0.265 -0.1491 0.1373 0.2773 A 0.263 0.0544 0.0713 0.4458 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3 
Genes in the osteoarthritis-associated signals with significantly different gene expression and/or protein abundance in intact 
compared to degraded articular cartilage. logFC: log2-fold change based on normalised values (increase means higher value in degraded 
cartilage); FDR: Bonferroni-Hochberg false discovery rate; - denotes that proteomics data were not available. 
 
Index variant Gene Position  
(chr:start-end) 
Distance from  
index variant (kb) 
Proteomics  
logFC 
Proteomics  
FDR q-value 
RNAseq  
logFC 
RNAseq 
 FDR q-value 
rs3771501 PCYOX1 2:70484518-  70508323 209.3 -0.27 0.0042 0.27 0.0047 
rs3771501 FAM136A 2:70523107- 70529222 188.4 - - -0.20 0.0066 
rs6516886 BACH1 21:30566392- 31003071 172.7 - - 0.32 0.0019 
rs6516886 MAP3K7CL 21:30449792-30548210 56.1 - - 0.41 0.0021 
rs11780978 BOP1 8:145486055-145515082 451.2 - - -0.26 0.0030 
rs116882138 PLAA 9:26904081-26947461 366 -0.07 0.601 0.20 0.0027 
rs375575359 ZNF382 19:37095719-37119499 233.8 - - 0.39 0.0031 
 
 
 
 
 
 
 
 
 
 
 
 
  
ONLINE METHODS 
Accuracy of self-reported data 
We evaluated the classification accuracy of self-reported disease status by estimating the 
sensitivity, specificity, positive predictive values (PPV) and negative predictive values (NPV) 
in the self-reported and hospital diagnosed disease definition datasets. We performed a 
sensitivity test to evaluate the true positive rate by calculating the proportion of individuals 
diagnosed with osteoarthritis that were correctly identified as such in the self-reported 
analysis, and a specificity test to evaluate the true negative rate by calculating the proportion 
of individuals not diagnosed with osteoarthritis that were correctly identified as such in the 
control set. The number of individuals overlapping between the self-reported (nSR=12,658) 
and hospital-diagnosed (nHD=10,083) datasets was nOVER=3,748. The total number of 
individuals was nTOT=138,997. Sensitivity =  
𝑛𝑂𝑉𝐸𝑅
𝑛𝐻𝐷
; Specificity =  
𝑛𝑇𝑂𝑇−(𝑛𝐻𝐷+ 𝑛𝑆𝑅−𝑛𝑂𝑉𝐸𝑅)
𝑛𝑇𝑂𝑇−𝑛𝐻𝐷
; PPV =
 
𝑛𝑂𝑉𝐸𝑅
𝑛𝑆𝑅
; NPV =  
𝑛𝑇𝑂𝑇−(𝑛𝐻𝐷+ 𝑛𝑆𝑅−𝑛𝑂𝑉𝐸𝑅)
𝑛𝑇𝑂𝑇−𝑛𝑆𝑅
. 
 
Discovery GWAS 
UK Biobank’s scientific protocol and operational procedures were reviewed and approved by 
the North West Research Ethics Committee (REC Reference Number: 06/MRE08/65). The 
1st UK Biobank release of genotype data includes ~150,000 volunteers between 40-69 
years old from the UK, genotyped at approximately 820,967 single nucleotide 
polymorphisms (SNPs). 50,000 samples were genotyped using the UKBiLEVE array and the 
remaining samples were genotyped using the UK Biobank Axiom array (Affymetrix; see 
URLs ). The UK Biobank Axiom is an update of UKBiLEVE and the two arrays share 95% of 
their content. In total, after sample and SNP quality control (QC), which was carried out 
centrally, 152,763 individuals and 806,466 directly typed SNPs remained. Phasing, 
imputation and derivation of principal components were also carried out centrally. Briefly, the 
combined UK10K/ 1000 Genomes Project haplotype reference panel was used to impute 
untyped variants through the IMPUTE3 program (see URLs). Following imputation, the 
number of variants reached 73,355,667 in 152,249 individuals. We performed additional 
quality control (QC) checks. We excluded samples with call rate ≤97%. We checked 
samples for gender discrepancies, excess heterozygosity, relatedness, ethnicity and we 
removed possibly contaminated and withdrawn samples. Following QC, the number of 
individuals was 138,997. We excluded 528 SNPs that had been centrally flagged as subject 
to exclusion due to failure in one or more additional quality metrics. 
 
To define osteoarthritis cases, we used the self-reported status questionnaire and the 
Hospital Episode Statistics data (Supplementary Table 3; Supplementary note). We 
conducted five osteoarthritis discovery GWAS and one sensitivity analysis, and the case 
strata were: self-reported osteoarthritis at any site n=12,658; sensitivity analysis (a random 
subset of the self-reported cohort equal to the sample size of the hospital diagnosed cohort) 
n=10,083; hospital-diagnosed osteoarthritis at any site based on ICD10 and/or ICD9 hospital 
records codes n=10,083; hospital-diagnosed hip osteoarthritis n=2,396; hospital-diagnosed 
knee osteoarthritis n= 4,462; and hospital-diagnosed hip and/or knee osteoarthritis n=6,586. 
We applied exclusion criteria to minimise misclassification in the control datasets to the 
extent possible (using approximately 4x the number of cases for each definition) 
(Supplementary Table 2, Supplementary Fig. 1). We restricted the number of controls used 
and did not utilise the full set of available genotyped control samples from UK Biobank in 
order to guard against association test statistics behaving anti-conservatively in the 
presence of stark case: control imbalance for alleles with minor allele count (MAC) <4004 
(analogous to MAF ~0.02 in the self-reported and hospital diagnosed osteoarthritis 
datasets). For the control set, we excluded all participants diagnosed with any 
musculoskeletal disorder, or with relevant symptoms or signs, such as pain and arthritis, and 
selected older participants to ensure we decrease the number of controls that might be 
  
diagnosed with osteoarthritis in the future, while keeping the number of males and females 
balanced (Supplementary Table 1).   
 
At the SNP level, we further filtered for Hardy Weinberg equilibrium (HWE) P≤10-6, 
MAF≤0.001 and info score<0.4 (Supplementary Fig. 1). We tested for association using the 
frequentist likelihood ratio test (LRT) and method ml in SNPTEST v2.5.239 with adjustment 
for the first 10 principal components in order to control for population structure. Power 
calculations were carried out using Quanto v1.2.4 (see URLs). 
 
Replication 
Two hundred independent and novel variants with P<1.0x10-5 in the discovery analyses 
were taken forward for in silico replication in an independent cohort from Iceland (deCODE) 
using fixed effects inverse-variance weighted meta-analysis in METAL40. One hundred and 
seventy three variants were present in the replication cohort. The remaining 27 variants had 
ambiguous alleles, i.e. incompatible due to alignment issues, and were not included in 
further analyses. The significance threshold for declaring association in the replication study 
was hence 0.05/173=2.9x10-4.The deCODE dataset comprised four osteoarthritis 
phenotypes: any osteoarthritis site (18,069 cases and 246,293 controls), hip osteoarthritis 
(5,714 cases and 199,421 controls), knee osteoarthritis (4,672 cases and 172,791 controls), 
and hip and/or knee osteoarthritis (9,429 cases and 199,421 controls). We performed meta-
analyses (across osteoarthritis definitions) using summary statistics from the UK Biobank 
osteoarthritis analyses and deCODE. We use P≤2.8x10-8 as the threshold corrected for the 
effective number of traits to report genome wide significance. 
 
Replication cohort: The information on hip, knee and vertebral osteoarthritis was obtained 
from Landspitali University Hospital electronic health records, Akureyri Hospital electronic 
health records and from a national Icelandic hip or knee arthroplasty registry41. Secondary 
osteoarthritis (e.g. Perthes disease, hip dysplasia), post-trauma osteoarthritis (e.g. ACL 
rupture) and those also diagnosed with rheumatoid arthritis were excluded from these lists. 
Only those diagnosed with osteoarthritis after the age of 40 were included. Hand 
osteoarthritis patients were drawn from a database of 9,000 hand osteoarthritis patients that 
was initiated in 197242. The study was approved by the Data Protection Authority of Iceland 
and the National Bioethics Committee of Iceland. Informed consent was obtained from all 
participants. 
 
Association with osteoarthritis-related endophenotypes 
The 9 replicating genetic loci were examined for association in radiographic osteoarthritis 
endophenotypes. This was done for 3 phenotypes: minimal Joint space width (mJSW), and 
two measures of hip shape deformities known as strong predictors for osteoarthritis: 
acetabular dysplasia (measured with Center Edge-angle), and cam deformity (as measured 
with alpha angle). For mJSW association statistics for the variants were looked-up in a 
previously published GWAS, which  joint analyzed data from the  Rotterdam Study I (RS-I), 
Rotterdam Study II (RS-II), TwinsUK, SOF and MrOS using standardized age, gender and 
population stratification (four principal components) adjusted residuals from linear 
regression17. For the two hip shape phenotypes, CE-angle and alpha angle were measured 
as previously published.  CE-angle was analyzed as a continuous phenotype. We conducted 
GWAS on a total of 6880 individuals from the Rotterdam Study I (RS-I), Rotterdam Study II 
(RS-II), Rotterdam Study III (RS-III) and CHECK43 datasets using standardized age, gender 
adjusted residuals from linear regression. For cam-deformity individuals with an alpha-angle 
>60° were defined as a case (n=639), while all others were controls (4339).  The GWAS was 
done on individuals from RS-I, RS-II and CHECK, using age, sex and principal components 
to adjust for population stratification as covariates. The results of the separate cohorts were 
combined in a meta-analysis using inverse variance weighting with METAL40. Genomic 
control correction was applied to the standard errors and P-values before meta-analysis. 
 
  
Functional genomics 
Patients and samples: We collected cartilage samples from 38 patients undergoing total joint 
replacement surgery: 12 knee osteoarthritis patients (cohort 1; 2 women, 10 men, age 50-88 
years); 17 knee osteoarthritis patients (cohort 2; 12 women 5 men, age 54-82 years); 9 hip 
osteoarthritis patients (cohort 3; 6 women, 3 men, age 44-84 years). We collected matched 
intact and degraded cartilage samples from each patient (Supplementary Note). Cartilage 
was separated from bone and chondrocytes were extracted from each sample. From each 
isolated chondrocyte sample, we extracted RNA and protein. All patients provided full written 
informed consent prior to participation. All sample collection, RNA and protein extraction 
steps are described in detail in44. 
 
Proteomics: Proteomics analysis was performed on intact and degraded cartilage samples 
from 24 individuals (15 from cohort 2, 9 from cohort 3). LC-MS analysis was performed on 
the Dionex Ultimate 3000 UHPLC system coupled with the Orbitrap Fusion Tribrid Mass 
Spectrometer. To account for protein loading, abundance values were normalised by the 
sum of all protein abundances in a given sample, then log2-transformed and quantile 
normalised. We restricted the analysis to 3917 proteins that were quantified in all samples. 
We tested proteins for differential abundance using limma45 in R, based on a within-
individual paired sample design. Significance was defined at 1% Benjamini-Hochberg False 
Discovery Rate (FDR) to correct for multiple testing. Of the 3732 proteins with unique 
mapping of gene name and Ensembl ID, we took forward 245 proteins with significantly 
different abundance between intact and degraded cartilage at 1% FDR. 
 
RNA sequencing: We performed a gene expression analysis on samples from all 38 
patients. Multiplexed libraries were sequenced on the Illumina HiSeq 2000 (75bp paired-end 
read length). This yielded bam files for cohort 1 and cram files for cohorts 2 and 3. The cram 
files were converted to bam files using samtools 1.3.146 and then to fastq files using 
biobambam 0.0.19147, after exclusion of reads that failed QC. We obtained transcript-level 
quantification using salmon 0.8.248 (with --gcBias and --seqBias flags to account for potential 
biases) and the GRCh38 cDNA assembly release 87 downloaded from Ensembl (see 
URLs). We converted transcript-level to gene-level count estimates, with estimates for 39037 
genes based on Ensembl gene IDs. After quality control, we retained expression estimates 
for 15994 genes with counts per million of 1 or higher in at least 10 samples. Limma-voom49 
was used to remove heteroscedasticity from the estimated expression data. We tested 
genes for differential expression using limma45 in R (with lmFit and eBayes), based on a 
within-individual paired sample design. Significance was defined at 1% Benjamini-Hochberg 
false discovery rate (FDR) to correct for multiple testing. Of the 14408 genes with unique 
mapping of gene name and Ensembl ID, we took forward 1705 genes with significantly 
different abundance between intact and degraded cartilage at 1% FDR. 
 
Fine-mapping 
We constructed regions for fine-mapping, by taking a window of at least 0.1 centimorgans 
either side of each index variant. The region was extended to the furthest variant with r2>0.1 
with the index variant within a 1Mb window. LD calculations for extending the region were 
based on whole-genome sequenced EUR samples from the combined reference panel of 
UK10K50 and 1000 Genomes Projects51. For each region we implemented the Bayesian fine-
mapping method CAVIARBF52, which uses association summary statistics and correlations 
among variants to calculate Bayes’ factors and posterior probabilities of each variant being 
causal. We assumed a single causal variant in each region and calculated 95% credible 
intervals, which contain the minimum set of variants that jointly have at least 95% probability 
of including the causal variant. We also applied the extended CAVIARBF method that uses 
functional annotation scores to upweigh variants according to their predicted functional 
scores. To this end, we downloaded pre-calculated CADD53 and Eigen54 scores from their 
equivalent websites. We observed better separation of severe-consequence genic variants 
with the CADD score and better separation of regulatory variants with the Eigen score, and 
  
therefore created a combined score, where splice acceptor, splice donor, stop lost, stop 
gained, missense and splice region variants were assigned their CADD-Phred score and the 
rest their Eigen-Phred score.  
 
Functional enrichment analysis 
We used genome-wide summary statistics to test for enrichment of functional annotations. 
We used GARFIELD55 with customized functional annotations, making use of the functional 
genomics data we generated in primary articular chondrocytes using RNA sequencing and 
quantitative proteomics. We defined differentially expressed genes separately at the RNA 
(transcriptional) level and at the protein level when comparing intact to degraded cartilage 
(1% FDR). We extended each differentially regulated gene by 5kb each side. Using 
GARFIELD’s approach, we calculated the effective number of independent annotations to be 
1.995, which led to an adjusted p-value significance level of 0.025. We tested for enrichment 
using variants with P<1.0x10-5 and no analysis surpassed the corrected significance 
threshold.   
 
LD regression 
We used LDHub56 [accessed 23-27 January] to estimate the genome-wide genetic 
correlation between each of the osteoarthritis definitions and 219 other human traits and 
diseases. In each analysis, we extracted variants with rsIDs (range 11,999,363-15,561,966) 
and uploaded the corresponding association summary statistics to LDHub, yielding 896,076-
1,172,130 variants overlapping with LDHub. We corrected for multiple testing by defining 
significance at 5% Benjamini-Hochberg False Discovery Rate (FDR) for each of the five 
osteoarthritis analyses. 
 
Mendelian randomization analysis 
We used Mendelian randomization (MR) to assess the potential causal role of the 
phenotypes identified in the LD score regression analysis on osteoarthritis. We also included 
birth weight and height (Supplementary Table 22). In all analyses, the primary outcome 
variable was self-reported osteoarthritis. We used data from hospital records (which were 
available for a much smaller number of individuals) as sensitivity analyses and to identify 
potential site-specific effects. 
 
Data sources: Genetic instruments were identified from publicly-available summary GWAS 
results through the TwoSampleMR R package, which allows extracting the data available in 
the MR-Base database57. Only results that combined both sexes were extracted. Preference 
was given to studies restricted to European populations to minimise the risk of bias due to 
population stratification; however, for a few traits those were either not available or 
corresponded to much smaller studies (Supplementary Table 22). However, this is unlikely 
to substantially bias the results because all studies employed correction methods, and even 
multi-ethnic studies are mostly composed of European populations. The exception was for 
number of children ever born and age of the individual when his/her first child was born: 
given that the GWAS of reproductive traits by Barban and colleagues58 was not available in 
MR-Base, we extracted summary association results for the variants that achieved genome-
wide significance directly from the paper, and used coefficients from each sex in sex-specific 
analyses. The search was performed on June 19, 2017. For each trait, all genetic 
instruments achieved the conventional levels of genome-wide significance (i.e., P<5.0x10-8) 
and were mutually independent (i.e. r²<0.001 between all pairs of instruments). 
 
Two-sample MR: For the exposure phenotypes with at least one genetic instrument 
available, we used two-sample MR analysis to evaluate their causal effect on osteoarthritis 
risk. The exceptions were smoking and reproductive traits, which were performed using one-
sample MR only due to the need of performing the analysis within specific subgroups. All 
summary association results used for two-sample MR are shown in Supplementary Table 
  
23, and Supplementary Table 24 provides an overall description of each set of genetic 
instruments. We applied the following methods: 
• Ratio method: for exposure phenotypes with only one genetic instrument available, MR 
was performed using the ratio method, which consists of dividing the instrument-outcome 
by the instrument-exposure regression coefficient. The standard error of the ratio 
estimate can be calculated by dividing the instrument-outcome standard error by the 
instrument-exposure regression coefficient. Confidence intervals and P-value were 
calculated using the Normal approximation. 
• Inverse-variance weighting (IVW): this method allows combination of the ratio estimates 
from multiple instruments into a single, pooled estimate. We used a multiplicative random 
effects version of the method, which incorporates between-instrument heterogeneity in 
the confidence intervals. 
• MR-Egger regression: this method yields consistent causal effect estimates even if all 
instruments are invalid, provided that horizontal pleiotropic effects are uncorrelated with 
instrument strength (i.e. the Instrument Strength Independent of Direct Effects – InSIDE – 
assumption holds).  
• Weighted median: this method allows consistent causal effect estimation even if the 
InSIDE assumption is violated, provided that up to (but not including) 50% of the weights 
in the analysis come from invalid instruments. 
• Mode-based estimate (MBE): the weighted MBE relies on the ZEro Modal Pleiotropy 
Assumption (ZEMPA), which postulates that the largest subgroup (or the subgroup that 
carries the largest amount of weight in the analysis) of instruments that estimate the 
same causal effect estimate is composed of valid instruments. This allows consistent 
causal effect estimation even if the majority of instruments are invalid. The stringency of 
the method can be regulated by the 𝜑 parameter. We tested two values of 𝜑: 𝜑=1 (ie, the 
default) and 𝜑=0.5 (half of the default, or twice as stringent).  
 
For exposure phenotypes with more than 1 but less than 10 genetic instruments, only the 
IVW method was applied. This was because the remaining methods are typically less 
powered and require a relatively large number of genetic instruments to provide reliable 
results. The degree of weak instrument bias (which corresponds to regression dilution bias in 
two-sample MR) for the IVW and MR-Egger methods was quantified using the 
𝐹𝑋𝐺−1
𝐹𝑋𝐺
 and 𝐼𝐺𝑋
2  
statistics, respectively. Both range from 0% to 100%, and 100 (1 −
𝐹𝑋𝐺−1
𝐹𝑋𝐺
) % and 
100(1 − 𝐼𝐺𝑋
2 )% can be interpreted as the amount of dilution in the corresponding causal 
effect estimates. Given that only genome-wide significant variants were selected as 
instruments, the 
𝐹𝑋𝐺−1
𝐹𝑋𝐺
 statistic will necessarily be high (approximately 95%, at least). 
However, the 𝐼𝐺𝑋
2  statistic depends both on instrument strength and heterogeneity between 
instrument-exposure associations, which implies that regression dilution bias in MR-Egger 
can be substantial even if instruments are individually strong. Indeed, for some traits the 𝐼𝐺𝑋
2  
statistic was very low (Supplementary Table 24). Therefore, all MR-Egger regression 
analyses were corrected for regression dilution bias using a Simulation Extrapolation 
(SIMEX) approach. 
 
Horizontal pleiotropy tests: We additionally assessed the robustness of our findings to 
potential violations of the assumption of no horizontal pleiotropy by applying two tests of 
horizontal pleiotropy. One of them was the MR-Egger intercept, which can be interpreted as 
the average instrument-outcome coefficient when the instrument-exposure coefficient is 
zero. If there is no horizontal pleiotropy, the intercept should be zero. Therefore, the 
intercept provides an indication of overall unbalanced horizontal pleiotropy . The second test 
was Cochran’s Q test of heterogeneity, which relies on the assumption that all valid genetic 
instruments estimate the same causal effect.  
 
  
Power calculations: We performed power calculations to estimate the power of our two-
sample MR analysis to detect odds ratios of 1.2, 1.5 and 2.0 (Supplementary note).  
 
One-sample MR: UK Biobank data were used to perform one-sample MR using the same 
genetic instruments than in the two-sample MR (Supplementary Note).  
 
 
DATA AVAILABILITY 
All RNA sequencing data have been deposited to the European Genome/Phenome Archive 
(cohort 1: EGAD00001001331; cohort 2: EGAD00001003355; cohort 3: 
EGAD00001003354). 
 
 
METHODS-ONLY REFERENCES 
 
 
 
39. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint 
method for genome-wide association studies by imputation of genotypes. Nat Genet 
39, 906-13 (2007). 
40. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of 
genomewide association scans. Bioinformatics 26, 2190-1 (2010). 
41. Franklin, J., Ingvarsson, T., Englund, M. & Lohmander, S. Association between 
occupation and knee and hip replacement due to osteoarthritis: a case-control study. 
Arthritis Res Ther 12, R102 (2010). 
42. Styrkarsdottir, U. et al. Whole-genome sequencing identifies rare genotypes in 
COMP and CHADL associated with high risk of hip osteoarthritis. Nat Genet 49, 801-
805 (2017). 
43. Wesseling, J. et al. CHECK (Cohort Hip and Cohort Knee): similarities and 
differences with the Osteoarthritis Initiative. Ann Rheum Dis 68, 1413-9 (2009). 
44. Steinberg, J. et al. Integrative epigenomics, transcriptomics and proteomics of patient 
chondrocytes reveal genes and pathways involved in osteoarthritis. Sci Rep 7, 8935 
(2017). 
45. Ritchie, M.E. et al. limma powers differential expression analyses for RNA-
sequencing and microarray studies. Nucleic Acids Res 43, e47 (2015). 
46. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 
2078-2079 (2009). 
47. Tischler, G. & Leonard, S. biobambam: tools for read pair collation based algorithms 
on BAM files. Source Code for Biology and Medicine 9, 13-13 (2014). 
48. Patro, R., Duggal, G., Love, M.I., Irizarry, R.A. & Kingsford, C. Salmon provides fast 
and bias-aware quantification of transcript expression. Nat Meth 14, 417-419 (2017). 
49. Law, C.W., Chen, Y., Shi, W. & Smyth, G.K. voom: precision weights unlock linear 
model analysis tools for RNA-seq read counts. Genome Biology 15, R29 (2014). 
50. UK10K Consortium et al. The UK10K project identifies rare variants in health and 
disease. Nature 526, 82-90 (2015). 
51. 1000 Genomes Project Consortium et al. A global reference for human genetic 
variation. Nature 526, 68-74 (2015). 
52. Chen, W. et al. Fine Mapping Causal Variants with an Approximate Bayesian Method 
Using Marginal Test Statistics. Genetics 200, 719-36 (2015). 
53. Kircher, M. et al. A general framework for estimating the relative pathogenicity of 
human genetic variants. Nat Genet 46, 310-5 (2014). 
54. Ionita-Laza, I., McCallum, K., Xu, B. & Buxbaum, J.D. A spectral approach integrating 
functional genomic annotations for coding and noncoding variants. Nat Genet 48, 
214-20 (2016). 
  
55. Iotchkova, V. et al. Discovery and refinement of genetic loci associated with 
cardiometabolic risk using dense imputation maps. Nat Genet 48, 1303-1312 (2016). 
56. Zheng, J. et al. LD Hub: a centralized database and web interface to perform LD 
score regression that maximizes the potential of summary level GWAS data for SNP 
heritability and genetic correlation analysis. Bioinformatics 33, 272-279 (2017). 
57. Hemani, G. et al. MR-Base: a platform for systematic causal inference across the 
phenome using billions of genetic associations. bioRxiv (2016). 
58. Barban, N. et al. Genome-wide analysis identifies 12 loci influencing human 
reproductive behavior. Nat Genet 48, 1462-1472 (2016). 
 
 
